Skip to search.
 TSX Down0.00% TSX Ventures Up0.36%

More On I.TO



News & Info


Analyst Coverage



IntelliPharmaCeutics International Inc. (I.TO)

3.32 Down 0.14(4.05%) 1:32PM EST
ProfileGet Profile for:
IntelliPharmaCeutics International Inc.
30 Worcester Road
Toronto, ON M9W 5X2
Canada - Map
Phone: 416-798-3001
Fax: 416-798-3007

Index Membership:N/A
Full Time Employees:N/A

Business Summary 

Intellipharmaceutics International Inc., a pharmaceutical company, engages in the research, development, and manufacture of novel and generic controlled and targeted release oral solid dosage drugs in Canada. The company develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in various stages of development in therapeutic areas, such as neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. Its lead product is Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for attention deficit hyperactivity disorders. The company also develops Rexista Oxycodone XR, an abuse and alcohol-deterrent controlled-release oral formulation of oxycodone hydrochloride for the relief of pain; Regabatin XR, a pregabalin extended-release capsule use for the management of neuropathic pain; Effexor XR, an extended-release capsule for oral administration that contains venlafaxine hydrochloride; Protonix, a delayed-release capsule for oral administration that contains pantoprazole sodium; and Glucophage, an oral antihyperglycemia drug used in the management of type 2 diabetes. In addition, its products include Seroquel XR, an oral psychotropic agent use for the treatment of schizophrenia, bipolar disorder, and major depressive disorder; Lamictal XR, an anticonvulsant drug used in the treatment of epilepsy; Keppra XR, an antiepileptic drug indicated for the treatment of partial onset seizures in patients with epilepsy; and Pristiq, an inhibitor use for the treatment of major depressive disorder. Intellipharmaceutics International Inc. has a license and commercialization agreement with Par Pharmaceutical, Inc. The company was founded in 1998 and is based in Toronto, Canada.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on IntelliPharmaCeutics International Inc.

Key Executives 
Dr. Isa Odidi Ph.D., MBA, 59
Co-Founder, Chairman, Chief Exec. Officer and Chief Scientific Officer
Dr. Amina Odidi Ph.D., 57
Pres, Chief Operating Officer, Co-Chief Scientific Officer and Director
Mr. Domenic Della Penna ,
Chief Financial Officer
Mr. John Newell Allport B.A.Sc., M.A., LL.B., 71
VP of Legal Affairs & Licensing, Sec., Director and Member of Corp. Governance Committee
Dr. Patrick N. Yat Ph.D., 59
VP of Pharmaceutical Analysis & Chemistry
Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in CAD.